1. Oganov RG, Kontsevaya AV, Kalinina AM. Economic cost of cardiovascular diseases in the Russian Federation. Cardiovascular therapy and prevention 2011; 4: 4–9. Russian (Оганов Р. Г., Концевая А.В., Калинина А. М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика 2011; 4: 4–9).
2. Lloyd-Jones D, Adams R, Carnethon M. et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480–6.
3. Chapman LS. Meta-evaluation of worksite health promotion economic return studies: 2005 update. Am J Health Promot 2005; 19: 1–11.
4. Goetzel RZ, Ozminkowski RJ. The Health and Cost Benefits of Work Site Health-Promotion Programs. Ann Rev Pub Health 2008; 29: 303–23.
5. Lindenbraten AL Resources require thrift. Social Security 2010; 6: 22–6. Russian (Линденбратен А.Л. Ресурсы требуют бережливости. Социальное страхование 2010; 6: 22–6).
6. Goldman L, Phillips KA, Coxson P, et al. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. JACC 2001; 38: 1012–7.
7. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008; 358 (7): 661–3.
8. Woolf SH. A Closer Look at the Economic Argument for Disease Prevention. JAMA 2009; 301 (5): 536–8.
9. Chazova LV. Multifactorial prevention of coronary heart disease in the population. Doctor diss Moscow 1984; 38 p. Russian (Чазова Л.В. Многофакторная профилактика ишемической болезни сердца среди населения. Автореф дисс докт мед наук. Москва 1984; 38 с).
10. Kalinina AM. The effect of prolonged multifactorial prevention of coronary heart disease by several indicators of health and life prognosis (10-year follow-up). Diss. Doctor. Moscow 1993; 46 p. Russian (Калинина А.М. Влияние длительной многофакторной профилактики ишемической болезни сердца на некоторые показатели здоровья и прогноз жизни (10-летнее наблюдение). Автореф дисс докт мед наук. Москва 1993; 46 с).
11. Kalinina AM Scientific evidence of cardiovascular prevention in medical practice (to the 35th anniversary of the start of the study, “Multi-factor prevention of coronary heart disease among the unorganized population”) 35 years –35 lessons. Cardiovascular Therapy and Prevention, 2010; 1: 14–20. Russian (Калинина А. М. Научные доказательные факты профилактики сердечно-сосудистых заболеваний в практическом здравоохранении (к 35-летию от начала исследования «Многофакторная профилактика ишемической болезни сердца среди неорганизованного населения») 35 лет — 35 уроков. Кардиоваскулярная терапия и профилактика 2010; 1: 14–20).
12. Chazova LV, IS Glazunov, Oleynikov SP, et al. Multifactorial prevention of coronary heart disease. Mосква 1983; 131. Russian (Чазова Л.В., Глазунов И.С., Олейников С.П. и др. Многофакторная профилактика ишемической болезни сердца. Москва 1983; 131 с).
13. Vorobyev PA, Avksenteva MV, Yurjev AS, et al. Clinical and economic analysis. M. Nyudiamed 2004; 404 p. Russian (Воробьев П. А., Авксентьева М.В., Юрьев А.С. и др. Клинико-экономический анализ. М.: Ньюдиамед 2004; 404 с).
14. Sarkar U, Ali S, Whooley MA. Self-Efficacy and Health Status in Patients With Coronary Heart Disease: Findings From the Heart and Soul Study Psychosomatic Medicine 2007; 69: 306–12.
15. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001; 32 (4): 964–72.
16. Caro J, Klittich W, McGuire A, et al, for the West of Scotland Coronary Prevention Study Group. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577–82.
17. Mihaylova B, Briggsb A, Armitage J, et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006; 333 (7579): 1145–8.
18. Grover S, Coupal L, Lowensteyn I. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost�effective? Can J Cardiol 2008; 24 (12): 891–8.
19. Bemelmans W, van Baal P, Wendel-Vos W, et al. The costs, effects and cost-effectiveness of counteracting overweight on a population level: a scientific base for policy targets for the Dutch national plan for action. Prev Med 2008; 46: 127–32.
20. Salkeld G, Phongsavan P, Oldenburg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy 1997; 41 (2): 105–19.
21. Finkelstein E, French S, Variyam JN, Haines PS. Pros and Cons of Proposed Interventions to Promote Healthy Eating. Am J Prev Med 2004; 27 (3): 163–71.
22. Tice JA, Ross E, Coxson PG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 2001; 286: 936–43.
23. Plans-Rubi P. Cost-Effectiveness of Cardiovascular Prevention Programs in Spain. Intern J Technology Assessment in Health Care 1998; 14: 320–30.
24. Tosteson АNA, Weinstein MC, Hunink MGM. Cost-Effectiveness of Populationwide Educational Approaches to Reduce Serum Cholesterol Levels. Circulation 1997; 95: 24–30.
25. Lindgren P, Fahlstadius P, Hellenius ML, et al. Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm — a stochastic model of exercise and dietary advice. Prev Med 2003; 36 (4): 403–9.
26. Lindholm L, Rosen M, Weinehall L, Asplund K. Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden. J Epidem Comm Health 1996; 50: 190–5.
